AI Insight
An experimental CRISPR-based therapy administered as a single dose reduced LDL cholesterol by up to 52.5% and triglycerides by up to 47.8% in patients with difficult-to-treat lipid disorders. These reductions persisted for at least one year after treatment, suggesting the gene editing approach provides long-lasting effects. The results represent a potential breakthrough for patients whose cholesterol levels are not adequately controlled by conventional medications.
Why it matters
This treatment could offer a one-time alternative to daily cholesterol medications for patients with genetic lipid disorders who don't respond well to standard therapies. The sustained effect over a full year suggests CRISPR gene editing may provide durable solutions for chronic metabolic conditions that currently require lifelong medication.
Understand the Science
A single dose of an experimental CRISPR therapy cut LDL cholesterol and triglycerides by about half in patients with difficult-to-treat lipid disorders. The reductions were still present one year later, with the highest dose lowering LDL by 52.5% and triglycerides by 47.8%.
Source: One CRISPR treatment cut “bad” cholesterol in half for a full year